Schering-Plough gears up for Saphris launch

Share this article:
Schering-Plough gears up for Saphris launch
Schering-Plough gears up for Saphris launch
Schering-Plough announced FDA approval on a key pipeline antipsychotic today, and is building a US sales force for the Q4 launch.

The product, Saphris (asenapine), received approval on two indications: for the acute treatment of schizophrenia in adults, and the acute treatment of manic or mixed episodes associated with bipolar 1 disorder. Saphris represents Schering's first entry into the CNS therapeutic area.

“Saphris is a five star pipeline drug that we have highlighted for investors, and was a major reason for Schering's acquisition of Organon BioSciences [in late 2007],” said Bob Consalvo, a Schering spokesperson. Saphris is the first Organon/Schering product approved in the US.

Consalvo noted that Schering's specialty sales force will handle Saphris, as opposed to its primary cast of reps, but declined to speculate about headcount. Schering has an “interest in CNS,” with other products in earlier stages of development for conditions like Parkinson's disease, said Consalvo. Campaign materials for Saphris are currently in development. The brand site is located at www.Saphris.com.

A Marketing Authorization Application (MAA) for asenapine, under the brand name Sycrest, is currently under review by the European Medicines Agency (EMEA) in Europe, according to a company release.

Share this article:

Email Newsletters

More in News

House bill would speed approval once EU OKs same product

House bill would speed approval once EU OKs ...

The Speeding Access to Already Approved Pharmaceuticals Act of 2014 would require FDA to expedite the review of pharmaceuticals that are already approved by the European Union

Rep access continues to shrink

Rep access continues to shrink

Sales reps are experiencing even more limited physician access, according to a report by Chicago consultancy ZS Associates.

Allergan touts reorg, plans to lay off 13% of workforce

Allergan touts reorg, plans to lay off 13% ...

Allergan's second-quarter earnings, and a new round of cuts, are now part of the Botox maker's record as it seeks to remain independent.